3D T-Cell Bioreactor Workflow for Scalable CAR T Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T-cell therapies face challenges in achieving consistent, scalable, and cost-effective manufacturing due to the high cost of production, limiting their accessibility to patients.
Innovation Solution
A bioreactor system comprising a 3D bioreactor for T-cell separation, activation, and transduction, followed by expansion in a separate reactor, utilizing precise geometric configurations and antibody coatings to facilitate integrated T-cell separation, activation, transduction, and expansion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional CAR T-cell manufacturing methods are used, then T-cell therapy can be produced, but the cost is relatively high limiting accessibility
Solution Approach 1:
The manufacturing process is divided into distinct modular stages: T-cell separation in a first bioreactor, activation and transduction in a second bioreactor, and expansion in a third bioreactor. This segmentation allows each stage to be optimized independently and enables parallel processing, reducing overall manufacturing time and cost while improving scalability and therapeutic accessibility.
2Reliability
If scalable bioreactor systems are implemented, then manufacturing consistency can be improved, but system complexity increases
Solution Approach 1:
The complex manufacturing process is segmented into three separate bioreactors, each performing a specific function with controlled parameters. This segmentation maintains manufacturing consistency within each module while reducing the complexity burden on any single device, as each bioreactor can be independently optimized and validated.
Solution Approach 2:
Each bioreactor in the segmented system is designed with universal features including controlled oxygenation, pH regulation, and temperature control, while being optimized for its specific function. This multi-functionality approach ensures consistent manufacturing outcomes across different stages without requiring entirely different complex systems for each process step.
3Loss of time
If integrated separation, activation, and transduction are performed in one bioreactor, then process time is reduced, but cell expansion efficiency decreases
Solution Approach 1:
The process is segmented such that separation, activation/transduction, and expansion occur in separate bioreactors. While this requires inter-bioreactor transfer time, each stage is optimized for its specific function, resulting in superior overall expansion efficiency compared to attempting all processes in a single reactor. The segmentation allows parallel optimization of each stage's parameters.
Solution Approach 2:
T-cells are fully activated and transduced in the second bioreactor before being transferred to the expansion bioreactor. This preliminary completion of activation and transduction ensures that cells are primed and ready for optimal expansion, preventing loss of expansion efficiency that would occur if these processes were concurrent with expansion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system enables efficient, scalable, and automated T-cell expansion, reducing costs and enhancing the availability of CAR T-cell therapies for cancer treatment.
Implementation Method 1
coating said 3D bioreactor with antibodies; binding T-cells to said antibodies
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
An apparatus and method for T-cell separation, activation, transduction and expansion. Three-dimensional (3D) bioreactors may be employed that include antibody coatings. Such 3D bioreactors can be employed for T-cell separation from peripheral blood mononuclear cells including attachment of T-cells to the 3D bioreactor surface for activation and transduction by lentivirus vectors to produce CAR T-cells. The CAR T-cells can then be expanded in a separate downstream bioreactor therein providing a scalable automated system.